<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876042</url>
  </required_header>
  <id_info>
    <org_study_id>360047-001</org_study_id>
    <nct_id>NCT02876042</nct_id>
  </id_info>
  <brief_title>BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>HFpEF</acronym>
  <official_title>BAROSTIM THERAPY ™ in Heart Failure With Preserved Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with
      the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the
      CE-Marked indication for resistant hypertension that also have evidence of heart failure with
      preserved ejection fraction (HFpEF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary:

      The CVRx BAROSTIM THERAPY in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry
      will be performed with subjects who have been recently implanted with the BAROSTIM NEO System
      in accordance with CE-Mark approved criteria for resistant hypertension and have evidence of
      HFpEF per the registry enrollment criteria. Subjects must be enrolled within 30 days from
      implant but prior to therapy activation. Up to 70 subjects will be enrolled at up to 10
      sites. Data should be obtained from standard of care measurements taken prior to implant, at
      enrollment/baseline, and at 3 and 6 months after the device was implanted, at which time each
      subject will be exited from the registry.

      Eligibility Criteria:

      The CE-Mark approved indications and contraindications for the BAROSTIM NEO system in the
      treatment of resistant hypertension include:

        -  Indications

             -  Systolic blood pressure greater than or equal to 140 mmHg, and

             -  Resistance to maximally tolerated therapy with a diuretic and two other
                anti-hypertension medications

        -  Contraindications

             -  Bilateral carotid bifurcations located above the level of the mandible

             -  Baroreflex failure or autonomic neuropathy

             -  Uncontrolled, symptomatic cardiac bradyarrhythmias

             -  Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation
                to be greater than 50%

             -  Ulcerative plaques in the carotid artery as determined by ultrasound or
                angiographic evaluation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Changes in Office Cuff Systolic Blood Pressure</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>Office cuff blood pressure measurement to be obtained from a time point prior to implant and as close to the implant procedure as possible (baseline), and at 3 and 6 months post-implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association Functional Classification</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>New York Heart Association Classification, if available, should be obtained from a time point prior to implant and as close to the implant procedure as possible (baseline), and at 3 and 6 months post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Left Ventricular Mass Index</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>An echocardiogram obtained prior to implant, and as close to the implant procedure as possible, will be utilized for the baseline measurement. An additional echocardiogram will be obtained at 3 and 6 months post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LA volume index</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>An echocardiogram obtained prior to implant, and as close to the implant procedure as possible, will be utilized for the baseline measurement. An additional echocardiogram will be obtained at 3 and 6 months post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in E/E' ratio</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>An echocardiogram obtained prior to implant, and as close to the implant procedure as possible, will be utilized for the baseline measurement. An additional echocardiogram will be obtained at 3 and 6 months post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NT-proBNP</measure>
    <time_frame>Pre-implant baseline, 6 months post-implant</time_frame>
    <description>If available, measurement should be obtained from a time point prior to implant and as close to the implant procedure as possible (baseline), and at 3 and 6 months post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate health care utilization over follow-up, such as heart failure hospitalizations</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>Health care utilization information is collected throughout follow-up.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BAROSTIM NEO™ System</intervention_name>
    <description>Implantation of the BAROSTIM NEO™ System</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The CVRx BAROSTIM THERAPY in Heart Failure with Preserved Ejection Fraction (HFpEF)
        Registry will be performed with subjects who have been recently implanted with the BAROSTIM
        NEO System in accordance with CE-Mark approved criteria for resistant hypertension and have
        evidence of HFpEF per the registry enrollment criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign an Ethics Committee (EC) approved informed consent form for the registry.

          -  Implanted with the BAROSTIM NEO system in accordance with CE-Mark approved indications
             and contraindications for resistant hypertension within 30 days prior to enrollment.

          -  BAROSTIM THERAPY not yet chronically activated.

          -  Pre-implant echocardiogram with left ventricular ejection fraction ≥ 50% within 30
             days prior to implant.

          -  On stable, maximally-tolerated, guideline-directed cardiovascular medications for at
             least 30 days prior to enrollment.

          -  Objective evidence of heart failure according to the following criteria:

               -  Hospitalization for heart failure within 12 months prior to enrollment OR

               -  Echocardiographic evidence of diastolic dysfunction (LA Volume Index &gt;34 ml/m2 OR
                  E/e &gt;13) within 30 days prior to enrollment OR

               -  NTproBNP &gt; 220 pg/mL or BNP &gt; 80 pg/mL (in atrial fibrillation, NTproBNP &gt; 600
                  pg/mL or BNP &gt; 200 pg/mL) within 30 days prior to enrollment

        Exclusion Criteria:

          -  Heart failure secondary to a reversible or treatable condition such as, cardiac
             structural valvular disease, acute myocarditis and pericardial constriction.

          -  Heart failure secondary to right ventricular failure or right ventricular myocardial
             infarction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burkert Pieske, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätmedizin Berlin - Charité</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liz Galle</last_name>
    <phone>763-416-2876</phone>
    <email>lgalle@cvrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Berlin Charité &amp; Deutschen Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lippe Klinikum</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Hellwig</last_name>
      <phone>+49 641 985 42632</phone>
      <email>gabriele.hellwig@med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Jörn Schmitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Neumann</last_name>
      <phone>+49 401818818635</phone>
      <email>chris.neumann@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Jochen Müller-Ehmsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonie Grossekettler</last_name>
      <phone>+49 6221 563 7758</phone>
      <email>leonie.grossekettler@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Philip Raake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kardiologie im Klinikum Ingolstadt</name>
      <address>
        <city>Ingolstadt</city>
        <zip>85049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln Herzzentrum</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatjana Schewior</last_name>
      <phone>+49 22147888273</phone>
      <email>tatjana.schewior@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Marcel Halbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marienkrankenhaus Siegen</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.barostimtherapy.com/</url>
    <description>BAROSTIM THERAPY website</description>
  </link>
  <reference>
    <citation>Georgakopoulos D, Little WC, Abraham WT, Weaver FA, Zile MR. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail. 2011 Feb;17(2):167-78. doi: 10.1016/j.cardfail.2010.09.004. Epub 2010 Oct 29. Review.</citation>
    <PMID>21300307</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

